A Multi-country, Cross-sectional Quantitative Study Exploring Awareness, Understanding, and Perceptions of the Relation Between Cardiorenal Metabolic Conditions and MASLD/MASH Among Healthcare Providers, People With MASLD/MASH, and At-risk Population
Completed
Conditions studied: Metabolic Dysfunction-associated Steatohepatitis (MASH)
In brief
The purpose of this study is to collect information for scientific research and to better understand awareness and to understand overall risk awareness, diagnoses and treatment related to liver related diseases. The study aims to collect valid responses through online questionnaires from the participants. This study is a survey-based study without collection of laboratory data. It will take the participant 25 minutes to complete the survey. The study is not related to any specific treatment options or pharmaceutical product.
Key facts
- Study ID
- NCT07201831
- Run by
- Novo Nordisk A/S
- People needed
- 1330
- Starts
- 2025-10-02
- Expected to finish
- 2026-01-17
- Last updated by the study team
- 2026-03-12
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- HCP inclusion criteria
- Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
- Male or female, age above or equal to 18 years at the time of signing informed consent.
- Licensed to practice medicine in one of the countries of interest: United States, Canada, France, Germany, Japan
- Must be a practicing endocrinologist, hepatologist, cardiologist, obesity specialist, primary care physician, radiologist, nurse practitioner or physician assistant (NP/PA US only)
- Must be at least "somewhat familiar" (as opposed to "not at all familiar) with Metabolic dysfunction-associated steatohepatitis (MASH) (do not need to be currently treating people with MASH) 6. Must have at least 2 years in practice 7. Must spend at least 50 percentage of their time in patient care
- Diagnosed patient inclusion criteria
- Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
- Male or female, age above or equal to 18 years at the time of signing informed consent.
- Diagnosis of MASH or Metabolic Associated Steatotic Liver Disease (MASLD) within past 24 months
- Live in one of the countries of interest: United States, Canada, France, Germany, Japan
- Have at least one comorbid condition: obesity, pre-diabetes, type 2 diabetes (T2D), metabolic syndrome, dyslipidaemia, hypertension, cardiovascular disease, chronic kidney disease
- At risk patient inclusion criteria
- Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
- Male or female, age above or equal to 18 years at the time of signing informed consent.
- Live in one of the countries of interest: United States, Canada, France, Germany, Japan
- Must have one or more risk factors associated with MASH [obesity, pre-diabetes, type 2 diabetes (T2D), metabolic syndrome, dyslipidaemia, hypertension, cardiovascular disease, chronic kidney disease], be diagnosed with steatosis (incidental finding) or have a blood test that shows raised liver enzymes.
You may not qualify if…
- Previous participation in this study. Participation is defined as having given informed consent in this study
- Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
Where it is running
- Novo Nordisk Investigational Site — Plainsboro, New Jersey, United States
- Novo Nordisk Investigational Site — Mississauga, Canada
- Novo Nordisk Investigational Site — Puteaux, France
- Novo Nordisk Investigational Site — Mainz, Germany
- Novo Nordisk Investigational Site — Tokyo, Japan
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.